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ABSTRACT
Objective: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore
patients with advanced fibrosis are prioritized. Although coupled with considerable side effects,
a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR)
following interferon-based therapy. The present study evaluates experimental clinical trial and
verifying real-life data with the aim of identifying patients with a high likelihood of favorable
outcome following short interferon-based treatment. Material and methods: The impact of
established response predictors, e.g. age, ITPA and IL28B genetic variants, IP-10, liver histopath-
ology and early viral kinetics on outcome was evaluated among HCV genotype 2/3 infected
patients enrolled in the NORDynamIC trial. Similarly outcome was evaluated among Finnish and
Swedish real-life genotype 2/3 infected patients treated for 12–16 weeks in accordance with
national guidelines. Results: In the NORDynamIC trial, age540 years or achieving HCV RNA51000
IU/mL day 7 were highly predictive of favorable outcome following 12 weeks therapy. Among 255
Finnish real-life patients below the age of 40 years treated for 12 weeks with interferon and
ribavirin, 87% of HCV genotype 2 and 79% of genotype 3 infected patients achieved SVR, and
among 117 Swedish real-life patients treated for 12–16 weeks, 97% of HCV genotype 2 and 94% of
genotype 3 infected achieved SVR. Conclusions: Short interferon-based therapy offers a high
likelihood of achieving SVR for selected HCV genotype 2/3 infected patients, and is an acceptable
option given that a thorough discussion of the side effects is provided prior to initiation.
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Recently major improvements in efficacy and side effects
have been reported regarding treatment for hepatitis C
virus (HCV) infection following the introduction of direct
antiviral agents (DAAs) [1–4]. This holds true especially for
HCV genotype 1, 2 and 4 infections, where interferon-
sparing regimens yield high rates of sustained virological
response (SVR) with side effect profiles often compatible
with placebo. However, with regards to treatment of HCV
genotype 3 infection, outcome following DAA-based
therapy thus far surprisingly has been poorer. When given
12 weeks of sofosbuvir and ribavirin therapy, significantly
lower SVR rates were achieved among patients infected
with HCV genotype 3 as compared with genotype 2, both
among treatment-naı¨ve as well as treatment experienced
patients [1,2]. These SVR rates were augmented upon
prolongation of treatment duration, but despite 24 weeks
of sofosbuvir and ribavirin, only 60% (27 of 45) of
treatment-experienced cirrhotic genotype 3 infected
patients achieved SVR [5]. When genotype 3 infected
cirrhotic patients were treated for 12 weeks with
daclatasvir and sofosbuvir without the addition of
ribavirin in the phase III ALLY-3 study, only 70% (21 of
30) achieved undetectable HCV RNA four weeks after
discontinuation of therapy, i.e. SVR4, in contrast to 94%
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(112 of 119) of non-cirrhotic patients [6], and relapse also
has been documented despite extension of this therapy
to 24 weeks and documented adherence [4]. Similarly,
when genotype 3 infected treatment-experienced cirrho-
tic patients were treated with ledipasvir, sofosbuvir and
ribavirin for 12 weeks, 73% achieved SVR12 as compared
to 89% of patients without cirrhosis [7].
Although the introduction of interferon-free treat-
ment regimens have entailed considerable improve-
ments, on a global perspective, health economics likely
will mandate the continued use of interferon-based
therapy as a therapeutic option for several years to
come, especially for patients with less advanced liver
fibrosis, even in more affluent regions [8]. Currently
these patients are not prioritized for DAA-based therapy,
and often are left waiting for possible future reductions
in treatment cost, or progression of fibrosis that would
merit therapeutic intervention. It is important to bear in
mind that approximately 80% of HCV genotype 2 or
3 infected patients achieve SVR following 24 weeks of
therapy with pegylated interferon-a (pegIFN-a) and
ribavirin combination therapy [9], albeit with consider-
able side effects which hampers adherence.
Generally a larger proportion of patients will tolerate
interferon-based combination therapy for 12 rather than
24 weeks [10]. In the previously reported NORDynamIC
trial, with 13% of enrolled patients having liver biopsy
verified cirrhosis, 56% of genotype 2 and 58% of
genotype 3 infected treatment-naı¨ve patients achieved
SVR following 12 weeks of therapy with pegIFN-a2a
180 mg weekly and ribavirin 800mg daily [10]. When
restricting this analysis to patients younger than 40 years,
80% achieved SVR following 12 weeks of therapy [10].
These findings subsequently have been incorporated into
the Finnish HCV treatment guidelines [11], where
patients infected with HCV genotype 2 or 3 below the
age of 40 years are recommended 12 weeks of interferon
and ribavirin combination therapy, whereas patients 40
years or above are offered therapy for 24 weeks.
Aside from age below 40, in the NORDynamIC study,
achieving HCV RNA51000 IU/mL by day 7, i.e. immedi-
ately prior to the second dose of peg-IFN, entailed
achieving SVR in 92% patients treated for 12 weeks
(ITT-analysis), and was superior to undetectable HCV RNA
week 4, i.e. rapid virological response (RVR), for predicting
favorable outcome [10,12,13]. Consequently both of
these two favorable response factors, i.e. age below 40
or HCV RNA below 1000 IU/mL day 7, have been
incorporated into the Swedish HCV treatment guidelines
[14] as suitable for selection of potential candidates for
shortened treatment duration, i.e. 12–16 weeks, among
genotype 2 or 3 infected patients, provided that no dose
reductions are required and RVR is achieved.
Recently, variants of the inosine triphosphate pyr-
ophosphatase (ITPase) gene (ITPA), which protect
against ribavirin-induced hemolytic anemia during ther-
apy for HCV [15], were reported to be significantly
associated with a ribavirin-like reduction of relapse risk
in the setting of the abovementioned NORDynamIC
study [16,17]. Subsequently this association between
ITPA variants and SVR also has been reported among
HCV genotype 1–4 infected patients treated with higher
ribavirin doses [18].
The aimof the present studywas to perform apost-hoc,
re-evaluation of the potential clinical utility of combin-
ations of favorable response predictors, including the
recently reported ITPA variants, following 12 weeks of
interferon and ribavirin therapy for treatment-naı¨ve
patients with chronic HCV genotype 2 or 3 infection in
the experimental phase III NORDynamIC trial (n¼ 382),
analyzing the results for HCV genotypes 2 and 3 infected
patients separately instead of together as previously
reported [10], as well as verifying the therapeutic
outcome among real-life Finnish and Swedish HCV
genotype 2 or 3 infected patients treated with short
duration interferon-based therapy in accordance with
respective national guidelines. The goal of this assess-
ment was to identify HCV genotype 2 or 3 infected
patients with a high likelihood of achieving SVR following
a shorter course of interferon-based therapy, as patients
with mild fibrosis currently are not candidates for signifi-




Three hundred and eighty-two treatment naı¨ve HCV
genotype 2 or 3 infected patients were included in a
phase III, open label, randomized, multicenter, investi-
gator-initiated trial (NORDynamIC) conducted at 31
centers in Denmark, Finland, Norway, and Sweden [10].
All patients were adults with compensated liver disease
and had detectable HCV RNA. At study entry, patients
were randomized to either 12 or 24 weeks of treatment
with 180 mg of peg-interferon a-2a once weekly and
800mg/day ribavirin. Patients having received at least
80% of the target dose of peg-interferon as well as at
least 80% of the target dose of ribavirin for at least 80%
of the target treatment duration (n¼ 285), were defined
as constituting the per-protocol (PP) population.
Adherence was monitored both by reporting of dose
reductions and missed doses in the case report forms
(CRF) and in the patient diaries in which patients
recorded each dosing. The two patients enrolled who




























were simultaneously infected with both HCV genotypes
2 and 3 were excluded from this study, as HCV
genotypes 2 and 3 were analyzed separately.
Real-life patients in Finland
Between January 2007 and December 2013, 115 HCV
genotype 2 infected and 333 HCV genotype 3 infected
patients were treated with pegIFN and 800mg daily
dosing of ribavirin at Helsinki University Hospital.
Patients below the age of 40 years received 12 weeks
of therapy unless they had unfavorable prognostic
factors e.g. pronounced steatosis, obesity, metabolic
syndrome or cirrhosis. Patients older than 40 years, and
those unfavorable pretreatment prognostic factors were
treated for 24 weeks.
Real-life patients in Sweden
An inquiry was initially performed among tertiary
treatment centers in Sweden, and seven centers
(Gothenburg, Karlstad, Ga¨vle, Bora˚s, Sko¨vde, Trollha¨ttan
and Halmstad) reported that they had offered a total of
32 HCV genotype 2, and 85 HCV genotype 3 infected
patients short course treatment as of December 2013.
These patients were selected on the basis of age below
40 years and/or achieving HCV RNA below 1000 IU/mL
day 7. One center (Halmstad) prescribed 800mg daily
dosing of ribavirin, and the remaining six centers used
11mg/kg per day dosing. Two centers (Gothenburg and
Karlstad) treated patients for 12 weeks, whereas the
remaining five gave most often 12 or on rare occasions
16 weeks of therapy.
The NORDynamIC-study patients
ITPA genotyping methods
SNPs were determined in plasma by allelic discrimination
using TaqMan SNP Assays (Life Technologies, Carlsbad,
CA): Assay ID C_29168507_10 for rs7270101, and
C_27465000_10 for rs1127354. Both SNPs were in
Hardy–Weinberg equilibrium.
Classification of predicted ITPase activity
This was achieved based on the compound genotype of
rs1127354 and rs7270101 as previously determined by
biochemical analyses [19–21] (detailed in Table I), i.e.
100% (CCrs1127354 AArs7270101), 60% (CCrs1127354
ACrs7270101), 30% (CCrs1127354 CCrs7270101), 25%
(CArs1127354 AArs7270101), 10% (CArs1127354 ACrs7270101)
and55% (AArs1127354 AArs7270101).
IL28B genotyping
DNA samples were genotyped for the rs12979860
polymorphism with TaqMan SNP genotyping assays
(Applied Biosystems Inc., Foster City, CA), using the ABI
7500 Fast real time thermocycler, according to manu-
facturers recommended protocols. TaqMan probes and
primers were designed and synthesized by Applied
Biosystems Inc.
IP-10 quantification in plasma
Quantification of IP-10 was performed using Quantikine
(R&D SYSTEMS, Minneapolis, MN), a solid-phase ELISA,
on plasma samples obtained during the week prior to
the start of therapy. All samples were stored at –70C
until assayed.
HCV RNA quantification
Plasma HCV RNA was determined using Cobas
AmpliPrep/COBAS TaqMan HCV Test (Roche
Diagnostics, Branchburg, NJ), which quantifies HCV
RNA with a limit of detection of 15 IU/mL.
Quantification was performed on days 0, 3, 7, 8, 29,
week 8, week 12, week 24 and 24 weeks after comple-
tion of therapy. All samples were frozen (–70C) and
centrally analyzed. Patients were classified as achieving
SVR if plasma HCV RNA was undetectable 24 weeks after
completion of therapy.
Liver biopsies
Liver biopsies were obtained from all patients within 24
months prior to study entry. The evaluation was
performed in a blinded fashion according to the Ishak
protocol [22]. Additionally steatosis was graded [23].
Statistical methods
All statistical analyses were performed by SN using IBM
SPSS statistics version 19.0 software package (IBM
Corporation, Somers, NY). All reported p-values are two-
sided, and p-values50.05 were considered significant.
Ethical considerations
Written informed consent was obtained from each
participating patient, and ethics committees in each
participating country approved the NORDynamIC study.
The study has been registered at the NIH trial registry
(ClinicalTrials.gov Identifier: NCT00143000). Ethics com-
mittees in Gothenburg, Sweden, and Helsinki, Finland




























have approved the reporting of real-life data from
routine clinical patients.
Results
The impact of baseline variables such as age, ITPase
activity, liver fibrosis, steatosis, IL28B genotype and
baseline IP-10, and on-treatment HCV RNA levels day 7
and week 4, as well as combination thereof on outcome
following 12 weeks of combination therapy in the
NORDynamIC trial were re-evaluated separately for
HCV genotypes 2 and 3 (PP analysis in Table I). The
highest positive predictive values were noted for HCV
RNA51000 IU/mL day 7, which was achieved by 26% of
enrolled patients (Figure 1), closely followed by age
below 40 years (Figure 2), and approximately half of all
patients fulfilled either of these criteria. More than 80%
of both genotype 2 and 3 infected patients fulfilling
these criteria, subsequently achieved SVR both in
intention-to-treat and PP analyses. If ITPase activity
5100% also was included, 65% of patients fulfilled any of
these criteria, however, the SVR rate among adherent,
HCV genotype 3 infected patients was below 80%
(Table I).
Since 2007, duration of pegIFN-a and ribavirin therapy
for HCV genotype 2/3 infection mainly has been
determined by age in Finland, with patients younger
than 40 years being treated for 12 weeks in contrast to
patients above 40 years, who received 24 weeks of
treatment (Table II). Interestingly, Finnish patients
infected with HCV genotype 2 were more likely to be
above 40 years of age as compared to genotype 3 (59%
age440 years for genotype 2 vs. 38% for genotype 3,
respectively; p50.0001, Chi-squared), similar to what has
previously been reported among the patients enrolled in
the NORDynamIC study (mean age 47.2 vs. 39.8 years for
genotypes 2 and 3, respectively, p50.0001 Mann–
Whitney U-test) [10]. Also a significantly higher propor-
tion of patients below 40 years of age achieved SVR than
older patients in spite of being prescribed only half the
treatment duration (81% vs. 73% for patients 540
vs.40 years of age respectively; p¼ 0.039, Chi-squared).
A non-significant trend was also noted towards greater
likelihood of achieving SVR among patients infected
Table I. Sensitivity, specificity, positive and negative predictive values of various markers on the likelihood of achieving SVR in
patients with HCV genotype 2 (n¼ 50) and genotype 3 (n¼ 111) included in the per-protocol analysis treated for 12 weeks.
Genotype 2 Genotype 3
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Age540 years 31% 95% 90% 50% 64% 76% 84% 53%
41% of patients (66/161) (9/29) (20/21) (9/10) (20/40) (47/73) (29/38) (47/56) (29/55)
ITPase activity5100% 57% 90% 89% 60% 38% 73% 72% 39%
35% of patients (54/154) (16/28) (18/20) (16/18) (18/30) (26/69) (27/37) (26/36) (27/70)
IL28B genotype (CC vs. CT/TT) 54% 43% 55% 41% 44% 58% 66% 36%
47% of patients (74/157) (15/28) (9/21) (15/27) (9/22) (31/70) (22/38) (31/47) (22/61)
Non-significant fibrosis 46% 58% 62% 42% 65% 70% 79% 53%
(Ishak stage 0–2) (13/28) (11/19) (13/21) (11/26) (42/65) (26/37) (42/53) (26/49)
50% of patients (74/149)
Non-cirrhosis 93% 21% 63% 67% 97% 19% 68% 78%
(Ishak stage 0–4) (26/28) (4/19) (26/41) (4/6) (63/65) (7/37) (63/93) (7/9)
90% of patients (134/149)
No steatosis 64% 58% 69% 52% 35% 78% 74% 41%
(Steatosis grade 0) (18/28) (11/19) (18/26) (11/21) (23/65) (29/37) (23/31) (29/71)
38% of patients (57/149)
IP-10 baseline5150 pg/mL 36% 47% 50% 33% 51% 69% 76% 41%
44% of patients (66/151) (10/28) (9/19) (10/20) (9/27) (35/69) (24/35) (35/46) (24/58)
IP-10 baseline5600 pg/mL 93% 11% 60% 50% 94% 14% 68% 56%
91% of patients (138/151) (26/28) (2/19) (26/43) (2/4) (65/69) (5/35) (65/95) (5/9)
HCV RNA day 751000 IU/mL 36% 100% 100% 54% 42% 97% 97% 46%
26% of patients (39/150) (10/28) (21/21) (10/10) (21/39) (28/67) (33/34) (28/29) (33/72)
HCV RNA undetectable week 4 (RVR) 76% 43% 65% 56% 72% 67% 81% 55%
62% of patients (98/158) (22/29) (9/21) (22/34) (9/16) (52/72) (24/36) (52/64) (24/44)
Age540 years or 57% 95% 94% 62% 78% 75% 86% 61%
HCV RNA day 751000 IU/mL (16/28) (20/21) (16/17) (20/32) (56/73) (27/36) (56/65) (27/44)
52% of patients (82/158)
Age540 years and RVR 24% 95% 88% 48% 45% 95% 94% 47%
27% of patients (43/161) (7/29) (20/21) (7/8) (20/42) (33/73) (36/38) (33/35) (36/76)
Age40 years and HCV RNA day 751000 IU/mL 25% 100% 100% 50% 12% 100% 100% 36%
10% of patients (16/158) (7/28) (21/21) (7/7) (21/42) (9/73) (36/36) (9/9) (36/100)
Age540 years or 79% 85% 88% 74% 83% 53% 78% 61%
ITPase Activity5100% or HCV RNA day 751000 IU/mL (22/28) (17/20) (22/25) (17/23) (60/72) (19/36) (60/77) (19/31)
65% of patients (102/156)




























with HCV genotype 2 vs. 3 (83% vs. 75% for genotypes 2
and 3, respectively). It should be noted that Finnish HCV
genotype 2/3 infected patients generally received
800mg daily flat dosing of ribavirin.
In Sweden, seven centers reported that they routinely
offered HCV genotype 2/3 infected patients younger
than 40 years of age and/or those achieving51000
IU/mL day 7 pegIFN-a and ribavirin combination therapy
for 12–16 weeks. Among HCV genotype 2 infected
patients, 97% achieved SVR, and among genotype 3
infected, 94% achieved SVR (Table III).
Discussion
The results of this study of both experimental clinical trial
and confirming real-life data suggest that combinations
of both baseline patient characteristics and/or on-treat-
ment responses can select for suitable HCV genotype 2 or
Figure 1. Proportion of HCV genotype 2 (A) or 3 (B) infected patients achieving SVR following 12 or 24 weeks included in the
intention-to-treat (ITT) and per-protocol (PP) analyses among patients achieving51000 vs.1000 IU/mL day 7 in the NORDynamIC
trial. The number of patients under each column reflects the ITT population.
Figure 2. Proportion of HCV genotype 2 (A) or 3 (B) infected patients achieving SVR following 12 or 24 weeks included in the
intention-to-treat (ITT) and per-protocol (PP) analyses among patients with age540 vs.40 years in the NORDynamIC trial. The
number of patients under each column reflects the ITT population.




























3 infected candidates with a high likelihood of achieving
SVR after as short as 12 weeks of interferon-based
combination therapy. From a clinical perspective, base-
line factors may be preferential as they do not require
initiation of therapy. To this end, age below 40 years is an
attractive selective characteristic as it does not require
laboratory analyses, and allows for the discussion of short
course interferon-based therapy at an early time-point
after referral to a tertiary treatment center. HCV RNA
below 1000 IU/mL was the best predictor of subsequently
achieving SVR, especially among adherent patients, but
obviously requires initiation of therapy.
Although the number of Swedish patients offered
short-duration treatment thus far has been substantially
lower than in Finland, slightly higher SVR rates have been
achieved. This possibly could be due tomore frequent use
of higher, weight-based ribavirin dosing (11mg/kg
weight per day), occasional prolongation of treatment
duration to 16 weeks, or more restrictive selection of
candidates deemed suitable, e.g. the provision that no
dose reductions are performed and RVR is achieved.
Additionally, the Finnish patient population included
those with advanced liver fibrosis, which also may have
contributed to the lower SVR rates achieved. However, it is
important to bear in mind that the general use of higher,
weight-based ribavirin dosing as compared to 800mg
daily dosingwill entail more side effects, primarily anemia.
The side effects of interferon-based combination
therapy are substantially more common and severe
than those associated with interferon-free DAA regi-
mens, and must be discussed with patients prior to
initiation of therapy as they may negatively impact both
on work and social life. Many side effects, however,
debut after 12 weeks of therapy, and thus can be
avoided by shorter duration. Unfortunately, neuro-
psychiatric symptoms such as depression often appear
as early as after two weeks [24]. The impact of these side
effects, however, can be ameliorated by routine moni-
toring using standardized questionnaires, and early
intervention [24]. The management of these side effects
demands additional laboratory monitoring and
resources of health-care providers, as well as other
incremental costs, e.g. sick leave. These issues impact on
the cost-effectiveness of interferon-based as compared
to DAA-based therapy. However, because of the sub-
stantial costs of DAA-based regimens, these treatment
options often are reserved for cirrhotic and pre-cirrhotic
patients. Thus, patients with mild fibrosis currently are
unlikely to be candidates for DAA-based therapy, and in
this light, 12 weeks of interferon-based treatment may
be attractive for some easy-to-cure HCV genotype 2/3
infected patients with favorable characteristics despite
potential side effects.
In conclusion, the results of this study suggest that as
short as 12 weeks of interferon and ribavirin therapy is
an acceptable alternative for selected HCV genotype 2/3
infected patients, given that a thorough discussion of
the potential side effects is provided prior to initiation.
Table II. Real-Life SVR data among Finish HCV genotype 2/3 infected patients where duration is
determined by age; Ribavirin 800 mg per day.
Genotype 2 Genotype 3
Year
540 years (12 weeks
of treatment)
40 years (24 weeks
of treatment)
540 years (12 weeks
of treatment)
40 years (24 weeks
of treatment)
2007 9 of 9 (100%) 8 of 9 (89%) 21 of 28 (75%) 12 of 19 (63%)
2008 9 of 11 (82%) 2 of 4 (50%) 30 of 37 (81%) 16 of 21 (76%)
2009 8 of 10 (80%) 11 of 13 (85%) 24 of 32 (75%) 16 of 25 (64%)
2010 2 of 2 (100%) 9 of 14 (64%) 27 of 31 (87%) 12 of 15 (80%)
2011 1 of 1 (100%) 7 of 7 (100%) 32 of 35 (91%) 10 of 12 (83%)
2012 5 of 6 (83%) 9 of 9 (100%) 14 of 19 (74%) 13 of 16 (81%)
2013 7 of 8 (88%) 8 of 12 (67%) 17 of 26 (65%) 7 of 17 (41%)
Total 41 of 47 (87%) 54 of 68 (79%) 165 of 208 (79%) 86 of 125 (69%)
Table III. Real-life SVR data among Swedish genotype 2/3 infected patients achieving51000 IU/mL day 7 or age540 years treated for
12–16 weeks.
Center HCV genotype 2 HCV genotype 3 Ribavirin dosing Treatment duration Criteria for patient selection
Gothenburg 6 of 6 16 of 17 11 mg/kg per day 12 weeks 51000 IU/mL day 7 or540 years
Karlstad 5 of 5 5 of 6 11 mg/kg per day 12 weeks 51000 IU/mL day 7
Ga¨vle 6 of 6 19 of 19 11 mg/kg per day 12–16 weeks 51000 IU/mL day 7
Bora˚s 7 of 8 9 of 10 11 mg/kg per day 12–16 weeks 51000 IU/mL day 7
Sko¨vde 2 of 2 18 of 20 11 mg/kg per day 12–16 weeks 51000 IU/mL day 7 or540 years
Trollha¨ttan 3 of 3 10 of 10 11 mg/kg per day 12–16 weeks 51000 IU/mL day 7 or540 years
Halmstad 2 of 2 3 of 3 800 mg daily 12–16 weeks 51000 IU/mL day 7 or540 years
Total 31 of 32 (97%) 80 of 85 (94%)
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